G E Messaris, M M Konstadoulakis, N Ricaniadis, E Leandros, G Androulakis, P C Karakousis
{"title":"III期恶性黑色素瘤患者的预后变量。","authors":"G E Messaris, M M Konstadoulakis, N Ricaniadis, E Leandros, G Androulakis, P C Karakousis","doi":"10.1080/110241500750009348","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Setting: </strong>Specialist hospital, USA.</p><p><strong>Subjects: </strong>130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.</p><p><strong>Main outcome measures: </strong>Survival and prognostic factors on multivariate analysis.</p><p><strong>Results: </strong>Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004).</p><p><strong>Conclusion: </strong>These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.</p>","PeriodicalId":22411,"journal":{"name":"The European journal of surgery = Acta chirurgica","volume":"166 3","pages":"233-9"},"PeriodicalIF":0.0000,"publicationDate":"2000-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/110241500750009348","citationCount":"10","resultStr":"{\"title\":\"Prognostic variables for patients with stage III malignant melanoma.\",\"authors\":\"G E Messaris, M M Konstadoulakis, N Ricaniadis, E Leandros, G Androulakis, P C Karakousis\",\"doi\":\"10.1080/110241500750009348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.</p><p><strong>Design: </strong>Retrospective study.</p><p><strong>Setting: </strong>Specialist hospital, USA.</p><p><strong>Subjects: </strong>130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.</p><p><strong>Main outcome measures: </strong>Survival and prognostic factors on multivariate analysis.</p><p><strong>Results: </strong>Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004).</p><p><strong>Conclusion: </strong>These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.</p>\",\"PeriodicalId\":22411,\"journal\":{\"name\":\"The European journal of surgery = Acta chirurgica\",\"volume\":\"166 3\",\"pages\":\"233-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2000-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/110241500750009348\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The European journal of surgery = Acta chirurgica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/110241500750009348\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European journal of surgery = Acta chirurgica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/110241500750009348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic variables for patients with stage III malignant melanoma.
Objective: To evaluate the prognostic factors for patients with stage III malignant melanoma and to identify patients at high risk of developing recurrent disease who may benefit from adjuvant therapy.
Design: Retrospective study.
Setting: Specialist hospital, USA.
Subjects: 130 patients with stage III malignant melanoma (according to the TNM classification), treated at the Roswell Park Cancer Institute between 1970 and 1992.
Main outcome measures: Survival and prognostic factors on multivariate analysis.
Results: Four factors were independent prognostic indicators for patients with stage III malignant melanoma: age >51 years (p = 0.008), >3 involved lymph nodes, (p = 0.03), the site of the primary tumour on head or trunk, (p = 0.007), and the presence of palpable lymph nodes (p = 0.004).
Conclusion: These prognostic factors help us to stratify patients into low and high-risk groups. High-risk patients may benefit from more aggressive adjuvant therapy in future trials of treatment of melanoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
